AstraZeneca’s Farxiga yields positive results in DAPA-CKD trial
AstraZeneca’s Farxiga is an oral sodium-glucose co-transporter-2 inhibitor. Credit: Bjoertvedt.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
